MedTrace Logo

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants

NCT06790290 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2025-09-02

No results posted yet for this study

Summary

Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants

Conditions

  • Pneumococcal Disease, Invasive

Interventions

BIOLOGICAL

Formulation B

IVT PCV-25

BIOLOGICAL

Formulation C

IVT PCV-25

BIOLOGICAL

Formulation D

IVT PCV-25

BIOLOGICAL

Prevnar20

20 valent pneumococcal conjugate vaccine

Sponsors & Collaborators

  • University of the Philippines-National Health Institute_Doña Nena Health Center

    collaborator UNKNOWN

  • Health Index Multispecialty Clinic

    collaborator UNKNOWN

  • Grand Centennial Homes Clinic

    collaborator UNKNOWN

  • Inventprise Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Inventprise Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
56 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-27
Primary Completion
2025-04-03
Completion
2026-12-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06790290 on ClinicalTrials.gov